Advertisement
Advertisement
U.S. markets close in 3 hours 34 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Oramed Pharmaceuticals Inc. (ORMP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.07+0.22 (+4.54%)
As of 12:26PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close4.85
Open4.83
Bid5.08 x 800
Ask5.08 x 2200
Day's Range4.88 - 5.25
52 Week Range3.59 - 31.54
Volume308,190
Avg. Volume830,500
Market Cap195.519M
Beta (5Y Monthly)2.03
PE Ratio (TTM)N/A
EPS (TTM)-1.00
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ORMP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Oramed Pharmaceuticals Inc.
    Technical Assessment: Bearish in the Intermediate-TermMarket sentiment remains in the tank and the stock market simply cannot put together a decent rally. The National Association of Active Investment Managers (NAAIM) exposure index has fallen back to 20%, an extremely low equity exposure and a very bearish stance toward equities. This is the second time the index has dropped to 20% in the past six weeks. The seven-week average of exposure has fallen to 30%, the lowest since the pandemic low, as well as in 2015, 2011, and 2008/2009.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • PR Newswire

    Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board

    Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Anne Peters, MD, to its Scientific Advisory Board.

  • PR Newswire

    Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes

    Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes." The patent addresses methods and compositions for treating diabetes mellitus through oral pharmaceutical compositions comprising insulin in combination with Glucagon-lik

  • PR Newswire

    Oramed to Present at H.C. Wainwright Global Investment Conference

    Oramed Pharmaceuticals Inc. (Nasdaq:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present an in-person company overview at the H.C. Wainwright Global Investment Conference, on May 25, 2022 in Miami, Florida.

Advertisement
Advertisement